Pfizer's Blood Cancer Drug Succeeds in Final-Stage Trial

• Elrexfio currently has FDA accelerated approval for multiple myeloma patients with at least four prior treatment lines; the successful trial tested it in earlier-line patients (one or more prior treatments)
• The drug showed clinically meaningful improvement in progression-free survival versus standard care, though overall survival data was not yet available at interim analysis
• Multiple myeloma represents 1-2% of all cancers with over 32,000 new U.S. cases annually; Elrexfio recorded $304 million in 2025 sales

Pfizer's Blood Cancer Drug Succeeds in Final-Stage Trial

Pfizer announced Wednesday that its drug Elrexfio met its primary endpoint in a late-stage clinical trial for treating multiple myeloma patients who received at least one prior line of treatment.

Key Trial Results:

• Elrexfio demonstrated clinically meaningful improvement in progression-free survival compared to standard care treatments
• The trial continues to assess overall survival, a key secondary endpoint, with data not yet available at this interim analysis
• Pfizer plans to discuss trial data with global health authorities

Regulatory Status:

The drug currently holds FDA accelerated approval for treating multiple myeloma patients who have undergone at least four prior treatment lines. This successful trial could expand its approved use to earlier-stage patients.

Financial Performance:

Elrexfio generated $304 million in sales during 2025.

Disease Context:

Multiple myeloma is a cancer affecting plasma cells in bone marrow that help fight infection. The disease represents 1-2% of all cancers and 10% of blood cancers, with over 32,000 new cases diagnosed annually in the United States.

Market Implications:

The positive trial results position Elrexfio for potential label expansion to a broader patient population requiring fewer prior treatments, which could significantly increase the drug's market opportunity and revenue potential. This development strengthens Pfizer's oncology portfolio amid ongoing efforts to diversify revenue streams beyond its COVID-19 products. The company's ability to secure regulatory approval for expanded use could provide meaningful growth in the competitive blood cancer treatment market.